文献速递类风湿关节炎其他结缔组织病

阿巴西普治疗类风湿关节炎合并间质性肺病患者:63例全国多中心研究

Abatacept in patients with rheumatoid arthritis and interstitial lung disease: A national multicenter study of 63 patients.
PubMed 文献 · Semin Arthritis Rheum · 2018-01-06

这项全国多中心、非对照、开放标签注册研究纳入63例接受阿巴西普治疗的类风湿关节炎合并间质性肺病患者,随访9.4±3.2个月后约三分之二患者稳定、四分之一在改良医学研究委员会量表上改善,用力肺活量和一氧化碳弥散量多数稳定或改善,11例因不良事件等停药,作者认为阿巴西普似乎对类风湿关节炎相关间质性肺病有效。

要点

  • 63例类风湿关节炎合并间质性肺病患者接受阿巴西普治疗,随访9.4±3.2个月。
  • 约三分之二患者病情稳定,四分之一在改良医学研究委员会量表上改善。
  • 11例(63例中)停用阿巴西普,主要因不良事件。

核心结论

  • 作者认为阿巴西普似乎对类风湿关节炎相关间质性肺病有效。

研究设计与样本

  • 全国多中心、非对照、开放标签注册研究,纳入63例接受阿巴西普治疗的类风湿关节炎合并间质性肺病患者。

主要发现

  • 63例患者中女性36例,研究时平均年龄63.2±9.8岁,类风湿关节炎和间质性肺病诊断中位病程分别为6.8年和1年。
  • 55例(87.3%)类风湿关节炎血清学阳性,15例(23.8%)间质性肺病的发生与合成或生物改善病情抗风湿药的使用密切相关。
  • 随访9.4±3.2个月后,三分之二患者保持稳定,四分之一在改良医学研究委员会量表上改善。
  • 用力肺活量在近三分之二受评估患者中保持稳定、五分之一改善;一氧化碳弥散量在近三分之二受评估患者中保持稳定、四分之一改善。
  • 12个月时,因持续呼吸道症状行胸部高分辨率CT的22例患者中,50%稳定、8例(36.4%)改善、3例恶化;63例中11例停用阿巴西普,主要因不良事件。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Interstitial lung disease (ILD) is one of the most serious complications of rheumatoid arthritis (RA). In the present study, we aimed to assess the efficacy of abatacept (ABA) in patients with ILD associated to RA. METHODS: National multicenter, non-controlled, open-label registry study of RA patients with ILD treated with ABA. RESULTS: 63 patients (36 women) with RA-associated ILD undergoing ABA therapy were studied. The mean ± standard deviation age at the time of the study was 63.2 ± 9.8 years. The median duration of RA and ILD from diagnosis were 6.8 and 1 year, respectively. RA was seropositive in 55 patients (87.3%). In 15 (23.8%) of 63 patients the development of ILD was closely related to the administration of synthetic or biologic disease modifying anti-rheumatic drugs. After a follow-up of 9.4 ± 3.2 months, two-thirds of patients remained stable whereas one-quarter experienced improvement in the Modified Medical Research Council scale. At that time forced vital capacity remained stable in almost two-thirds of patents and improved in one out of five patients assessed. Also, diffusing capacity of the lung for carbon monoxide remained stable in almost two-thirds and showed improvement in a quarter of the patients assessed. At 12 months, 50% of the 22 patients in whom chest HRCT scan was performed due persistence of respiratory symptoms showed stabilization, 8 (36.4%) improvement and 3 worsening of the HRCT scan pattern. Eleven of 63 patients had to discontinue ABA, mainly due to adverse events. CONCLUSION: ABA appears to be an effective in RA-associated ILD.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Fernández-Díaz C, Loricera J, Castañeda S, et al. Abatacept in patients with rheumatoid arthritis and interstitial lung disease: A national multicenter study of 63 patients. Semin Arthritis Rheum. 2018. PMID: 29422324. doi:10.1016/j.semarthrit.2017.12.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。